Benefits Seen With Apalutamide Plus ADT in Metastatic Castration-Sensitive Prostate Cancer

Date Posted: 
2019-06-03
Dr. Chi

The TITAN clinical trial has demonstrated that the addition of apalutamide to androgen-deprivation therapy significantly improved radiographic progression-free survival and overall survival in patients with metastatic castration-sensitive prostate cancer. These results were presented by Dr. Kim Chi at ASCO on May 31, and were written up on ASCO Daily News on June 1.  Dr. Chi is first author on the study which was published in the New England Journal of Medicine on May 31.

 

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Terry Fox

Terry Fox Run - September 15, 2019

This year's Terry Fox Run takes place on Sunday September 15, in locations across Canada.  Please consider donating to or joining our TFRI-VPC team as we raise funds to enable The Terry Fox Foundation & The Terry Fox Research Institute to continue their support of innovative and progressive cancer research programs

Employment

Work at the Vancouver Prostate Centre

Monday, July 8, 2019

Dr. Flannigan to lead clinical trial for scrotal pain treatment

Monday, June 3, 2019

Benefits Seen With Apalutamide Plus ADT in Metastatic Castration-Sensitive Prostate Cancer

Dr. Chi